Hutch News
The New Yorker spotlights Fred Hutch’s pioneering cancer research
‘The Promise and Price of Cellular Therapies’ by Siddhartha Mukherjee traces journey from bone marrow transplantation to immunotherapy
“Exciting” but early results in trial of immunotherapy for myeloma
Cancer cells disappeared rapidly in patients with high-risk, treatment-resistant disease
Fred Hutch at ASH: Combo CAR T-cell therapies, long-term outcomes for CAR T patients, early findings on a CAR T for multiple myeloma, gene therapy for sickle cell, and T cells and the microbiome
The 60th American Society of Hematology Annual Meeting will take place Dec. 1–4 in San Diego
Two new grants to fuel metastatic breast cancer research
Drs. Erica Goddard and Mark Headley will use their awards to study how breast cancer cells spread to distant organs – and how to stop them.
Forbes '30 Under 30' lists Hutch immunotherapy researcher Alex Salter
Grad student on short list of young health care influencers
Stronger and faster is not always better
From the Riddell, Paulovich Labs, Clinical Research Division and Gottardo Lab, Vaccine and Infectious Disease Division.
First in-depth profile of CAR T-cell signals suggests how to improve immunotherapy
A Science Signaling paper reports how two common CAR designs impact T-cell efficacy against cancer in the laboratory
Nanoparticles open doors to cancer-fighting CAR T cells
Tiny liposome-based drug carriers make tumors more vulnerable to targeted immunotherapy
Fred Hutch at ASCO
Immunotherapy advances, insights into health economics and leadership awards dominate oncology gathering
Dr. Reema Jain developing methods to isolate, manipulate blood stem cells for T-cell therapy
Funding from Immunotherapy Integrated Research Center supports postdoc’s work
Jump-starting innovative projects exploring pathogen-associated cancers
Pathogen-Associated Malignancies Integrated Research Center awards first round of pilot funding supporting researchers studying H. pylori, EBV and the microbiome
How new drugs become available to more patients
Filling in the unknowns on the balance between risk and benefit
CAR T cells manufacture upgrades
From the Till lab, Clinical Research Division
10 highlights of Fred Hutch science in 2017
A look back at notable discoveries in cancer immunotherapy, HIV prevention and more
New insights into CAR T-cell therapy's potential side effects
<p>Detailed study of cytokine release syndrome and neurologic toxicities could help make emerging cancer immunotherapies safer</p>
First systematic study of infections after CAR T-cell therapy
“Benchmark” research could help reduce complications of emerging immunotherapy
Mourning the loss of Dr. Oliver 'Ollie' Press
Lymphoma physician-scientist, leader and mentor made lifesaving contributions to the development of targeted cancer therapies
Looking for 'a multitude of ways to cure HIV'
HIV researchers draw hope from cancer immunotherapies — and inspiration from Timothy Ray Brown
Dr. Carl June weaves together HIV and cancer research to advance cures for both
CAR T-cell pioneer and one-time bone marrow transplant fellow will give keynote at HIV cure conference
Promising results in trial of engineered T cells in high-risk leukemia
High response rates to experimental immunotherapy in patients with treatment-resistant chronic lymphocytic leukemia
Fred Hutch Statement Regarding FDA Briefing About CAR T-cell Therapy
Fred Hutch immunotherapy expert comments on FDA staff review of CAR T-cell therapy
Forum at Fred Hutch focuses on the hottest developments in cancer immunotherapy
Immune-based treatments move from the fringes to the spotlight
Implanted scaffold with T cells rapidly shrinks tumors
A biopolymer structure enriched with nutrients shows how immunotherapy could be adapted for solid tumors, according to a study in The Journal of Clinical Investigation.